Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen has dipped below $220/share for the first time in some months. This marks what I believe to be a very clear opportunity for investors looking to get into Amgen.

Amgen Is A 'Buy' With A 12-15% Annual Upside

Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated advanced colorectal cancer. Related Link:   Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.

Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer

THOUSAND OAKS, Calif., Sept. 16, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer (CRC).

LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer

Merck

The recent weakness across the pharmaceutical space has created strong opportunities for value investors. I highlight 2 beaten-down blue chips that could drive strong total returns from their current prices.

Build Your Dividend Factory: 2 Coiled Springs Set To Soar

THOUSAND OAKS, Calif., Sept. 14, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and The Lundquist Institute today announced that Diadem Biotherapeutics, Inc., has been awarded the first Amgen Golden Ticket in Southern California.

Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA

Morgan Stanley

Amgen Inc. (AMGN) CEO Bob Bradway Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

THOUSAND OAKS, Calif., Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m.

Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference

THOUSAND OAKS, Calif., Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2021 Congress.

Amgen To Webcast Investor Call At ESMO 2021

THOUSAND OAKS, Calif., Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding inflammation pipeline and marketed portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, which will take place virtually Sept.

Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021

TOKYO, Sept. 13, 2021 /PRNewswire/ -- Kyowa Kirin Co., Ltd.

Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress

New data from the phase 3 trial of tezepelumab bodes well for the drug candidate becoming a significant revenue producer in the near future.

These Promising Clinical Results Could Be Huge for Amgen Investors

American Express

Boeing

Chevron

Dow Inc

Intel

Coca-Cola

Visa

Verizon

Walgreens

Walmart

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." - DowJones&Co. Thirty Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated net-gains ranged 13.84%-30.73% topped by CVX 9/7/21.

September Dogs Of The Dow Show None Worth Buying For Dividend Income

THOUSAND OAKS, Calif., Sept. 9, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 19th Annual Global Healthcare Conference at 2:45 p.m.

Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

But making Amgen an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of AMGN entered into oversold territory, changing hands as low as $215.41 per share.

Amgen Becomes Oversold

Amgen Inc (NASDAQ: AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib).  Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients

Bank of Nova Scotia

PROG Holdings

The market keeps grinding higher, and stocks are now 31% historically overvalued. A market downturn is inevitable. But that doesn't mean world-class blue-chips can't be safely purchased if you have the right watchlist and tools. 33% of the DK 500 Master List is reasonably priced.

3 Wonderful Blue-Chips You Can Safely Buy With The Market At Record Highs

Amgen Inc. (AMGN) Management Presents at Citi's 16th Annual BioPharma Virtual Conference (Transcript)

THOUSAND OAKS, Calif., Sept. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRASG12C inhibitor approved in the U.S., in the treatment of previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21

Alibaba

Dollar Tree

Looking for a deal? Don't overlook these stocks.

3 Beaten-Up Stocks for Bargain Hunters

Bristol-Myers

Enterprise Products Partners

Pembina Pipeline

Reinsurance Group of America

Unum

In this article, we're looking at the companies I consider the most investable for September of 2021. I look for investment-graded dividend-paying stocks with a conservative RoR of no less than 15% over a 3-4-year period.

Undervalued Dividend Stocks For September With 10-20% Upside

THOUSAND OAKS, Calif., Sept. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1 Tezepelumab is a potential first-in-class treatment that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a broad population of patients with severe asthma.2,3 Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps

THOUSAND OAKS, Calif., Sept. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 16th Annual BioPharma Conference at 1:25 p.m.

Amgen to Present at the 16th Annual Citi BioPharma Conference

Broadcom

Bank of Montreal

Clorox

Darden Restaurants

Evergy Inc

General Mills

Kellogg

Kimberly-Clark

Lockheed Martin

M&T Bank

PepsiCo

Principal Financial Group

Philip Morris

Restaurant Brands

Rogers Communications

Royal Bank of Canada

Southern Company

Sempra Energy

Toronto-Dominion Bank

Truist Financial

WEC Energy Group

There are 23 High-Yield Dividend Stocks on the September 2021 watchlist. The watchlist gained 1.81% in August and is up over 40% since November 2020.

High Yield Dividend Stocks For September 2021

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Down 2.2% Since Last Earnings Report: Can It Rebound?

Home Depot

Texas Instruments

Home Depot, Intel, and PepsiCo are among the stocks identified as having low ESG risk, yields of at least 2%, and large market caps.

News for Amgen Stock (AMGN)